The role of mineralocorticoid receptor antagonists (MRAs) in very old patients with heart failure

Heart Failure Reviews

Volumn 17, Issue 4-5, 2012, Pages 573-579

  Pitt, Bertram ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Aldosterone; Heart failure; Mineralocorticoid receptor antagonist

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; ALDOSTERONE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; LOSARTAN; MINERALOCORTICOID RECEPTOR; MINERALOCORTICOID RECEPTOR ANTAGONIST; SPIRONOLACTONE; UNCLASSIFIED DRUG;

AGE; AGED; ATHEROSCLEROSIS; CHRONIC KIDNEY DISEASE; COMORBIDITY; CORONARY ARTERY DISEASE; DISEASE CONTROL; DISEASE MODEL; DISEASE RESISTANCE; DRUG COST; DRUG EFFICACY; GYNECOMASTIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART FAILURE WITH PRESERVED LEFT VENTRICULAR EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; HYPERTENSION; MASTALGIA; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NONHUMAN; OBESITY; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; SLEEP APNEA SYNDROME; VISCERAL OBESITY;

AGED; AGING; ALDOSTERONE; COMORBIDITY; HEART FAILURE; HUMANS; MINERALOCORTICOID RECEPTOR ANTAGONISTS;

EID: 84862638785     PISSN: 13824147     EISSN: 15737322     Source Type: Journal    
DOI: 10.1007/s10741-011-9286-7     Document Type: Review

References (54)

1. B Pitt F Zannad WJ Remme R Cody A Castaigne A Perez J Palensky J Wittes 1999 The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators N Engl J Med 341 709 717 10471456 10.1056/NEJM199909023411001 1:CAS:528: DyaK1MXmtVyrurk%3D
2. B Pitt W Remme F Zannad J Neaton F Martinez B Roniker R Bittman S Hurley J Kleiman M Gatlin 2003 Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 1309 1321 12668699 10.1056/NEJMoa030207 1:CAS:528:DC%2BD3sXis1ehurY%3D
3. F Zannad JJ McMurray H Krum DJ van Veldhuisen K Swedberg H Shi J Vincent SJ Pocock B Pitt 2011 Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 11 21 21073363 10.1056/NEJMoa1009492 1:CAS:528:DC%2BC3MXisValuw%3D%3D
4. P Weidmann S De Myttenaere-Bursztein MH Maxwell J de Lima 1975 Effect on aging on plasma renin and aldosterone in normal man Kidney Int 8 325 333 538 10.1038/ki.1975.120 1:CAS:528:DyaE28XktFahug%3D%3D
5. J Henschkowski AE Stuck BM Frey G Gillmann B Dick FJ Frey MG Mohaupt 2008 Age-dependent decrease in 11beta-hydroxysteroid dehydrogenase type 2 (11beta-hsd2) activity in hypertensive patients Am J Hypertens 21 644 649 18443572 10.1038/ajh.2008.152 1:CAS:528:DC%2BD1cXmt1yjsLg%3D
6. JW Funder 2005 Rales, ephesus and redox J Steroid Biochem Mol Biol 93 121 125 15860254 10.1016/j.jsbmb.2004.12.010 1:CAS:528:DC%2BD2MXjs1Crur4%3D
7. B Bocchi S Kenouch M Lamarre-Cliche M Muffat-Joly MH Capron J Fiet G Morineau M Azizi JP Bonvalet N Farman 2004 Impaired 11-beta hydroxysteroid dehydrogenase type 2 activity in sweat gland ducts in human essential hypertension Hypertension 43 803 808 14981055 10.1161/01.HYP.0000121362.64182.ad 1:CAS:528:DC%2BD2cXit12msbc%3D
8. AW Krug L Allenhofer R Monticone G Spinetti M Gekle M Wang EG Lakatta 2010 Elevated mineralocorticoid receptor activity in aged rat vascular smooth muscle cells promotes a proinflammatory phenotype via extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase and epidermal growth factor receptor-dependent pathways Hypertension 55 1476 1483 20421514 10.1161/HYPERTENSIONAHA.109.148783 1:CAS:528:DC%2BC3cXmt1alu78%3D
9. RS Vasan S Demissie M Kimura LA Cupples N Rifai C White TJ Wang JP Gardner X Cao EJ Benjamin D Levy A Aviv 2008 Association of leukocyte telomere length with circulating biomarkers of the renin-angiotensin-aldosterone system: the framingham heart study Circulation 117 1138 1144 18268147 10.1161/CIRCULATIONAHA.107.731794 1:CAS:528:DC%2BD1cXitlyrsL4%3D
10. A Benetos JP Gardner M Kimura C Labat R Nzietchueng B Dousset F Zannad P Lacolley A Aviv 2005 Aldosterone and telomere length in white blood cells J Gerontol A Biol Sci Med Sci 60 1593 1596 16424294 10.1093/gerona/60.12.1593
11. H Kai F Kuwahara K Tokuda T Imaizumi 2005 Diastolic dysfunction in hypertensive hearts: roles of perivascular inflammation and reactive myocardial fibrosis Hypertens Res 28 483 490 16231753 10.1291/hypres.28.483 1:CAS:528:DC%2BD2MXhtFSnsbfN
12. F Zannad F Alla B Dousset A Perez B Pitt 2000 Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (rales). Rales investigators Circulation 102 2700 2706 11094035 1:STN:280:DC%2BD3M%2FmtVyntQ%3D%3D
13. ME Safar BI Levy H Struijker-Boudier 2003 Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases Circulation 107 2864 2869 12796414 10.1161/01.CIR.0000069826.36125.B4
14. C Savoia RM Touyz F Amiri EL Schiffrin 2008 Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients Hypertension 51 432 439 18195160 10.1161/HYPERTENSIONAHA.107.103267 1:CAS:528:DC%2BD1cXotlSrug%3D%3D
15. C Yoshida A Goda Y Naito A Nakaboh M Matsumoto M Otsuka M Ohyanagi S Hirotani M Lee-Kawabata T Tsujino T Masuyama 2011 Role of plasma aldosterone concentration in regression of left-ventricular mass following antihypertensive medication J Hypertens 29 357 363 21052021 10.1097/HJH.0b013e32834103d4 1:CAS:528:DC%2BC3cXhs1aks7vF
16. B Pitt N Reichek R Willenbrock F Zannad RA Phillips B Roniker J Kleiman S Krause D Burns GH Williams 2003 Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4e-left ventricular hypertrophy study Circulation 108 1831 1838 14517164 10.1161/01.CIR.0000091405.00772.6E 1:CAS:528: DC%2BD3sXnvVajur8%3D
17. PM Mottram B Haluska R Leano D Cowley M Stowasser TH Marwick 2004 Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure Circulation 110 558 565 15277317 10.1161/01.CIR.0000138680.89536.A9 1:CAS:528:DC%2BD2cXlvF2htbs%3D
18. Aldosterone antagonist therapy for adults with heart failure and preserved systolic function (2007) Available at http://www.Clinicaltrials.Gov
19. G Remuzzi D Cattaneo N Perico 2008 The aggravating mechanisms of aldosterone on kidney fibrosis J Am Soc Nephrol 19 1459 1462 18550649 10.1681/ASN.2007101079 1:CAS:528:DC%2BD1cXhtVWltrzE
20. NC Edwards RP Steeds PM Stewart CJ Ferro JN Townend 2009 Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial J Am Coll Cardiol 54 505 512 19643310 10.1016/j.jacc.2009.03.066 1:CAS:528:DC%2BD1MXhtFaisLfP
21. LM Mosso CA Carvajal A Maiz EH Ortiz CR Castillo RA Artigas CE Fardella 2007 A possible association between primary aldosteronism and a lower beta-cell function J Hypertens 25 2125 2130 17885557 10.1097/HJH.0b013e3282861fa4 1:CAS:528:DC%2BD2sXhtVKhsbnK
22. MN Pratt-Ubunama MK Nishizaka RL Boedefeld SS Cofield SM Harding DA Calhoun 2007 Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension Chest 131 453 459 17296647 10.1378/chest.06-1442 1:CAS:528:DC%2BD2sXjtlWqt74%3D
23. A Tomaschitz S Pilz E Ritz A Meinitzer BO Boehm W Marz 2010 Plasma aldosterone levels are associated with increased cardiovascular mortality: the ludwigshafen risk and cardiovascular health (luric) study Eur Heart J 31 1237 1247 20200015 10.1093/eurheartj/ehq019 1:CAS:528:DC%2BC3cXmtFyrtbc%3D
24. S Rajagopalan D Duquaine S King B Pitt P Patel 2002 Mineralocorticoid receptor antagonism in experimental atherosclerosis Circulation 105 2212 2216 11994257 10.1161/01.CIR.0000015854.60710.10 1:CAS:528:DC%2BD38XktlOku7Y%3D
25. S Keidar M Kaplan E Pavlotzky R Coleman T Hayek S Hamoud M Aviram 2004 Aldosterone administration to mice stimulates macrophage nadph oxidase and increases atherosclerosis development: a possible role for angiotensin- converting enzyme and the receptors for angiotensin ii and aldosterone Circulation 109 2213 2220 15123520 10.1161/01.CIR.0000127949.05756.9D 1:CAS:528:DC%2BD2cXjs1eis74%3D
26. S Takai D Jin M Muramatsu K Kirimura H Sakonjo M Miyazaki 2005 Eplerenone inhibits atherosclerosis in nonhuman primates Hypertension 46 1135 1139 16203870 10.1161/01.HYP.0000184640.81730.22 1:CAS:528:DC%2BD2MXhtFCisbvK
27. JA Leopold A Dam BA Maron AW Scribner R Liao DE Handy RC Stanton B Pitt J Loscalzo 2007 Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity Nat Med 13 189 197 17273168 10.1038/nm1545 1:CAS:528:DC%2BD2sXhsVykur0%3D
28. R Rocha JW Funder 2002 The pathophysiology of aldosterone in the cardiovascular system Ann N Y Acad Sci 970 89 100 12381544 10.1111/j.1749-6632. 2002.tb04415.x 1:CAS:528:DC%2BD38XovFCht74%3D
29. GE Callera RM Touyz RC Tostes A Yogi Y He S Malkinson EL Schiffrin 2005 Aldosterone activates vascular p38map kinase and nadph oxidase via c-src Hypertension 45 773 779 15699470 10.1161/01.HYP.0000154365.30593.d3 1:CAS:528:DC%2BD2MXisV2jtbc%3D
30. MG Usher SZ Duan CY Ivaschenko RA Frieler S Berger G Schutz CN Lumeng RM Mortensen 2010 Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice J Clin Invest 120 3350 3364 20697155 10.1172/JCI41080 1:CAS:528:DC%2BC3cXhtFertbvK
31. NJ Brown S Nakamura L Ma I Nakamura E Donnert M Freeman DE Vaughan AB Fogo 2000 Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo Kidney Int 58 1219 1227 10972684 10.1046/j.1523-1755. 2000.00277.x 1:CAS:528:DC%2BD3cXmslehtr4%3D
32. Swedberg K, Zannad F, McMurray J, Krum H, Veldhuisen D, Shi H, Vincent J, Pitt B. Eplerenone and atrial fibrillation in mild systolic heart failure-results from the eplerenone in mild patients hospitalization and survival study in heart failure (emphasis-hif) study. Lancet Submitted for publication
33. S Shibata M Nagase S Yoshida H Kawachi T Fujita 2007 Podocyte as the target for aldosterone: roles of oxidative stress and sgk1 Hypertension 49 355 364 17200434 10.1161/01.HYP.0000255636.11931.a2 1:CAS:528:DC%2BD2sXivFKqsw%3D%3D
34. G Remuzzi D Cattaneo N Perico 2008 The aggravating mechanisms of aldosterone on kidney fibrosis J Am Soc Nephrol 19 1459 1462 18550649 10.1681/ASN.2007101079 1:CAS:528:DC%2BD1cXhtVWltrzE
35. NC Edwards RP Steeds PM Stewart CJ Ferro JN Townend 2009 Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial J Am Coll Cardiol 54 505 512 19643310 10.1016/j.jacc.2009.03.066 1:CAS:528:DC%2BD1MXhtFaisLfP
36. BF Palmer 2004 Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system N Engl J Med 351 585 592 15295051 10.1056/NEJMra035279 1:CAS:528:DC%2BD2cXmtF2ru7o%3D
37. J Ezeckowitz F McAllister 2009 Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials Eur Heart J 30 469 477 10.1093/eurheartj/ehn543
38. DN Juurlink MM Mamdani DS Lee A Kopp PC Austin A Laupacis DA Redelmeier 2004 Rates of hyperkalemia after publication of the randomized aldactone evaluation study N Engl J Med 351 543 551 15295047 10.1056/NEJMoa040135 1:CAS:528:DC%2BD2cXmtF2rtb0%3D
39. B Pitt SD Anker DA Bushinsky DW Kitzman F Zannad IZ Huang 2011 Evaluation of the efficacy and safety of rly5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the pearl-hf) trial Eur Heart J 32 820 828 21208974 10.1093/eurheartj/ehq502 1:CAS:528:DC%2BC3MXkt1Kgs7o%3D
40. P Kolkhof I Flamme L Figueroa-Perez L Baerfacker E Hartmann M Rinke S Schafer 2006 Cardiac and renal protection by a new mineralocorticoid receptor antagonist in salt-sensitive arterial hypertension Eur Heart J 27 110
41. DA Calhoun D Jones S Textor DC Goff TP Murphy RD Toto A White WC Cushman W White D Sica K Ferdinand TD Giles B Falkner RM Carey 2008 Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the american heart association professional education committee of the council for high blood pressure research Hypertension 51 1403 1419 18391085 10.1161/HYPERTENSIONAHA.108.189141 1:CAS:528:DC%2BD1cXlvFaitLw%3D
42. SD Persell 2011 Prevalence of resistant hypertension in the united states, 2003-2008 Hypertension 57 1076 1080 21502568 10.1161/HYPERTENSIONAHA. 111.170308 1:CAS:528:DC%2BC3MXmt1GhtL4%3D
43. N Chapman J Dobson S Wilson B Dahlof PS Sever H Wedel NR Poulter 2007 Effect of spironolactone on blood pressure in subjects with resistant hypertension Hypertension 49 839 845 17309946 10.1161/01.HYP.0000259805.18468.8c 1:CAS:528:DC%2BD2sXivVamt78%3D
44. J Vaclavik R Sedlak M Plachy K Navratil J Plasek J Jarkovsky T Vaclavik R Husar E Kocianova M Taborsky 2011 Addition of spironolactone in patients with resistant arterial hypertension (aspirant): a randomized, double-blind, placebo-controlled trial Hypertension 57 1069 1075 21536989 10.1161/ HYPERTENSIONAHA.111.169961 1:CAS:528:DC%2BC3MXmt1Ght7Y%3D
45. GP Rossi A Sacchetto P Visentin C Canali GR Graniero P Palatani AC Pessina 1996 Chyanges in left ventricular anatomy and function in hypertension and primary aldosteronism Hypertension 27 1039 1045 8621194 1:STN:280: DyaK283gvVOktw%3D%3D
46. B Pitt N Reichek R Willenbrock F Zannad RA Phillips B Roniker J Kleinman S Krause D Burns GH Williams 2003 Effect of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E -left ventricular hypertrophy study Circulation 108 1831 1838 14517164 10.1161/01.CIR.0000091405.00772.6E 1:CAS:528: DC%2BD3sXnvVajur8%3D
47. EL Schriffrin 2006 Effects of aldosterone on the vasculature Hypertension 47 312 318 10.1161/01.HYP.0000201443.63240.a7
48. M Yamamuro M Yoshimura M Nakayama K Abe H Sumida S Sugiyama Y Saito K Nakao H Yasue H Ogawa 2008 Aldosterone, but not angiotensin ii, reduces angiotensin converting enzyme 2 gene expression levels in cultured neonatal rat cardiomyocytes Circ J 72 1346 1350 18654024 10.1253/circj.72.1346 1:CAS:528:DC%2BD1cXhtVajtrvO
49. S Keidar A Gamliel-Lazarovich M Kaplan E Pavlotzky S Hamoud T Hayek R Karry Z Abassi 2005 Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients Circ Res 97 946 953 16179584 10.1161/01.RES.0000187500.24964.7A 1:CAS:528:DC%2BD2MXhtFCitr%2FN
50. CA Farquharson AD Struthers 2000 Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin i/angiotensin ii conversion in patients with chronic heart failure Circulation 101 594 597 10673249 1:CAS:528:DC%2BD3cXhtlGntL4%3D
51. JI Davies M Band A Morris AD Struthers 2004 Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes Diabetologia 47 1687 1694 15365622 10.1007/s00125-004-1510-8 1:CAS:528:DC%2BD2cXpsFKrtrc%3D
52. M Yamaji T Tsutamoto C Kawahara K Nishiyama T Yamamoto M Fujii M Horie 2010 Effect of eplerenone versus spironolactone on cortisol and hemoglobin a (c) levels in patients with chronic heart failure Am Heart J 160 915 921 21095280 10.1016/j.ahj.2010.04.024 1:CAS:528:DC%2BC3cXhsVGitbnI
53. RS Vasan S Demissie M Kimura LA Cupples N Rifai C White TJ Wang JP Gardner X Cao EJ Benjamin D Levy A Aviv 2008 Association of leukocyte telomere length with circulating biomarkers of the renin-angiotensin-aldosterone system: the framingham heart study Circulation 117 1138 1144 18268147 10.1161/CIRCULATIONAHA.107.731794 1:CAS:528:DC%2BD1cXitlyrsL4%3D
54. A Benetos JP Gardner M Kimura C Labat R Nzietchueng B Dousset F Zannad P Lacolley A Aviv 2005 Aldosterone and telomere length in white blood cells J Gerontol A Biol Sci Med Sci 60 1593 1596 16424294 10.1093/gerona/60.12.1593